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1201-83 ete-Adrenergic Inhibition of Leptin Production is 
Attenuated in Obese Individuals 
John M. Dooo. Alexei V. Agapitov, William G. Haynes, Christine A, Sinkey, Vireod K. 
Somers, Bradley G. Phillips, University of Iowa, Iowa Ci~ Iowa. 
Background: Leptin regulates body weight and may affect cardiovascular function. Leptin 
expression from adipocytes is suppressed by beta-receptor stimulation. Obese subjects 
have high leptin levels and are at increased risk for cardiovascular disease, We tested 
the hypothesis that suppression of leptin production from adipocytes following beta- 
receptor stimulation is attenuated in obese subjects. 
Methods: We studied 8 obese (age 35 ± 3 yrs, BMI 35 ± 2 kg/m2) and 8 age and gender 
matched lean controls (age 35 ± 3 yrs, BMI 24 ± 1 kg/m2). All subjects were norrnoten- 
sire, free of disease and were not taking any medications. In a randomized fashion, sub- 
jects received either a 4 hour infusion of normal saline or isoproterenol (to increase 
resting heart rate by 25%) on two separate days. Blood samples for plasma leptin were 
drawn at baseline and at 30 minute intervals during both infusions. 
Results: Leptin levels decreased by 7.8 ± 1.5% at the end of isoproterenol and increased 
by 3.1 ± 4,8% during normal saline in obese subjects (p < 0.05). in controls, leptin 
decreased by 16,8 ± 3.4% and 9.0 ± 4,8% with isoproterenol and normal saline, respec- 
tively (p < 0.05). During isoproterenol, the maximum percent decrease from baseline in 
leptin was 10.3 ± 3.3% in obese subjects and 19.2 ± 2.1% in lean controls (p < 0.02). The 
area under the curve (AUC) for percent change in leptin levels with isoproterenol was 
significantly less in obese subjects compared to lean controls (1799 ± 287 versus 2818 ± 
203, p < 0.05), The infusion rate of isoproterenol in obese subjects was 0.47 ± 0,1 rncg/ 
rain and 0.36 ± 0.06 mcg/min in controls (p = 0.05). 
Conclusion: Isoproterenol significantly decreased plasma leptin levels in both obese and 
tean subjects compared to normal saline. Beta-adrenergic stimulation that induced com- 
parable increases in heart rate in both Jean and obese subjects resulted in a lower level 
of leptin suppression in obese subjects. This blunted suppression of leptin production is 
even evident dudng higher doses of isoproterenol in obese subjects. Thus, there appears 
to be an attenuated beta-adrenergic suppression of leptin production in obese individu- 
als. 
1201-84 Difference of High-Sensitive C-Reactive Protein Levels 
in Patients Treated With Stat lns,  Aspirin, and 
Angiotensln II Modulators 
Toshihiro Takeda. Shire Hoshida, Shinichiro Suna, Masayuki Taniike, Yasuyuki Egami, 
Ryu Shutta, Masayoshi Kawabata, Masami Nishino, Hideo Tanahashi, Jun Tanouchi, 
Yoshio Yamada, Osaka Rosai Hospital, ok. 
Objectives The anti-inflammatory effects of statins, aspirin, and angiotensin II modula- 
tors (A II-M), such as angiotensin-converting enzyme inhibitors and angiotensin II type I 
receptor blockades, were examined by measuring serum high-sensitive C-reective pro- 
tein (hs-CRP) levels in patients with and without ischemic heart disease (IHD). Back- 
ground Statins, aspirin and A II-M may have a clinical anti-inflammatory action. Although 
statins have been shown to reduce CRP levels, the relationship between the effects of 
statins, aspirin and A II-M on CRP levels remains to be determined. Methods We exam- 
ined serum hs-CRP levels in consecutive patients who were scheduled for coronary 
angiography with (n=979, 65± 1 years, male/female 731/248) and without (n=200, 64±1 
years, male/female 102/98) IHD. The blood was withdrawn on the day of catheterization. 
Hyperlipidemia (HL) was defined as total cholesterol >220 and/or triglycerides >150 rag/ 
dl. Results In IHD patients, hs-CRP levels were significantly higher than in non-IHD 
patients (0.34±0.02 vs 0.26±0.03 mg/dl, p<0.05), although no difference in hs-CRP lev- 
els was observed between patients with and without HL in each group. The low levels of 
hs-CRP in the non-IHD patients were not reduced by the treatment with statins, but the 
high levels of hs-CRP in the IHD patients were significantly reduced by the treatment with 
statins (0.27±0.02 mg/dl, p<0.05). In all patients included, neither aspirin nor A II-M had 
any effect on hs-CRP levels in both groups. Interestingly, however, in the patients not 
treated with statins, A II-M, but not aspirin, significantly reduced hs-CRP levels only in 
IHD patients (A II-M, 0.41±0.04 vs 0.32±0.03 mg/dl, p<0.05; aspirin, 0.34±0.03 vs 
0.38¢0.03 mg/dl, ns). Conclusions Statins have an anti-inflammatory action assessed 
by measurement of CRP levels in IHD, but not in non-IHD, patients. A II-M also have an 
anti-inflammatory action only in IHD patients, but the effect is smaller than that of statins 
in terms of CRP levels. 
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1202-85 Fol ic Acid Supplementation Substantially Reduces 
Hyperhomocysteinemia Induced by Fenoflbrate 
Voitec h Melenovskv, Tomas Btulc, Barbora Grauova, Dan Wichterle, Viktor Kozich, 
Jakub Krijt, Tomas Haas, Richard Ceska, 3rd Department of Medicine, Genera/ 
University Hospital, Prague, Czech Republic, Institute of Inherited Metabolic 
Diseases, 1st Medical Facul~ Prague, Czech Republic. 
BACKGROUND: Plasma homocysteine (Hcy) is an independent risk factor of atheroscle- 
rosis. An increase of Hcy levels during treatment with fibrates has been reported. This 
phenomenon may explain lower efficacy of fibrates on mortality. The effect of Folic acid 
(FA) on fibrate-induced Hcy elevation has never been studied. 
METHODS: 37 subjects (15 wo, 50±10y) with hypedipidemia were randomized to 8 
weeks of treatment with micronised fenofibrate (F) 200rag/day or F 200 rag/day + Folic 
acid 5 mg/day (F+FA). Subjects with vitamin B use or deficiency, diabetes, renal or thy- 
roid disease were excluded. Blood lipids, creatinine (Creat), plasma FA, cysteine (Cys) 
and Hcy (by HPLC) were determined before and after treatments. The between-group 
differences were tested by ANCOVA. 
RESULTS: Serum Hcy increased after F by 52.5% (from 11.5 ± 3.0 to 17 ± 6.5 pmol/I), 
after F+FA only by 12.5% (from 10.4 ± 1.9 to 11.7± 2.5 ~mol/I), (p = 0.001). Cys 
increased after F by 14% (from 321 ± 32 to 366 ± 53 IJmol/I) and after F+FA by 16,6% 
(from 292 ± 34 to 340 ± 30 pmol/I), (NS). Craat increased after F by 20% (from 90 ± 12 to 
108 ± 14 pmol/I), after F+FA by 9% (from 90 ± 10 to 98 ± 10 pmol/I), (p = 0.015). Plasma 
folate was unchanged after F, after F+FA increased by 152% (from 5.7 ± 1.7 to 14.4 ± 3.9 
mg/I). Groups did not differ in lipid levels. 
CONCLUSIONS: Fenofibrate-inducad Hcy elevation can be effectively reduced by Folic 
acid co-administretion. Folic acid can enhance therapeutic efficacy of fibrates. 
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1202-86 Secretory Phospholipase Is Related to Other Coronary 
Heart Disease Risk Factors 
Sara Mobaspori. Christine C. Tangney, Liping Lu, Robert S. Rosenson, Rush Heart 
Institute, Chicago, Illinois, Northwestern University Medical School, Chicago, Illinois. 
Background: Secretory Phospholipase (sPLA2) remodels LDL and HDL particles, and 
may contribute to vascular inflammatory. This cross-sectional analysis evaluated the 
relations between sPLA 2 and certain CHD risk factors, 
Methods: Plasma lipoprotsin subclasses and particle sizes were measured by nuclear 
magnetic resonance (NMR) spectroscopy (LipoMed, Raleigh, NC). Enzyme immunoas- 
says were used to determine sPLA 2 (Cayman Chemical, Ann Arbor, Ml) and high-sensi- 
tivity C-reactive protein or hs-CRP (Wampole, Cranbury, N J). Pearson correlations were 
done between Iog-transformod sPLA 2 levels and hs-CRP, fipoproteins, age, gender, 
race, BMI (body mass index), hypertension, diabetes, and use of tobacco or hormones. 
Patients were divided into two groups: high sPLA 2 levels (Kugiyama st al., Circulation 
1999;100:1280) and low sPLA 2 levels. Mann Whitney U tests and multiple logistic 
regression analyses was performed between the two groups. 
Results: Ninety-six subjects (40 female, 56 male) with average age of 49 years. The 
means ± SD (medians) of biochemical variables include TG, 254 ± 363 (162) mg/dL; TC, 
229 ± 58 mg/dL; HDL-C, 40±14 mg/dL; LDL-C, 150 ± 53 rng/dL; sPLA2, 176.6 ± 200 
(125.8) pg/mL; hs-CRP, 3.65 ± 6.72 (1.61) mg/dL Log-transformed sPLA2 levels were 
correlated with hs-CRP (r=.60, p<0.00005), HDL size (r=.22, p=0.044), age (r=.26, 
p=0.0f2) and BMI (r=.23, p=0.033). Significantly higher hs-CRP (p=0.00005), larger HDL 
particles, greater BMI (p=0.003), more diabetes, but lower TG (p=0.02) were found in 
subjects with higher sPLA2 (_> 246pg/mL) levels as compared to those with lower levels. 
Conclusion: sPLA 2 levels is a novel inflammatory marker that is elevated in diabetics 
and associated with certain other CHD risk factors characteristic of the metabolic syn- 
drome. 
1202-87 Predictors of 13-Year Changes in the Total Cholesterol 
to High-Density Lipoprotein Cholesterol Ratio 
Richard E. Scranton. Howard D. Sesso, Robert J. Glynn, J. M. Gaziano, Massachusetts 
Veterans Affairs Epidemiology, Research, and Information Center, Boston, 
Massachusetts. 
Background: Many clinical and lifestyle factors modify the total cholesterol to HDL (TC/ 
HDL) ratio, yet few studies have determined what predicts changes in this ratio over time. 
We examined the predictors of the 13-year change in TC/HDL ratio among 4,543 men 
free of coronary artery disease from the Physicians' Health Study who provided baseline 
and follow-up blood samples. 
Methods: Baseline coronary risk factors were included in multivariate linear regression 
models to determine significant predictors of a change in the TC/HDL ratio. The final 
model had an r 2 of .38. 
Results: These men had a mean age of 48.7 + 7 years with a mean total and HDL cho- 
lesterol in 1982 of 214 + 36 mg/dL and 42 _+15 mg/dL, respectively. After a mean follow 
up of 13 years, average total cholesterol decreased by 8 mg/dL, HDL increased by 1 mgJ 
dL and the ratio decreased by 0.38. The parameter estimates and P values for the 
change in TC/HDL ratio are as follows: baseline TC/HDL ratio (-0.49, p<0.0001), age in 
years (-0.03, p<O.0001), systolic blood pressure per mmHg (+0.01, p<0.002), alcohol 
consumption of 1-6 drinkshNeek (-0.16, p=0.02), alcohol consumption of -> 1 ddnks/day (- 
0.25, p=0.004), body mass index > 25 kg/m 2 (+0.27, p<0.0001), hypertension treatment 
(-0.34, p=0 .0002), and hyperlipidemia treatment (-0.65, p<0. 0001). Smoking history, 
exercise, and diabetes were not significant but were included in the model. The exclusion 
of 92 individuals with an MI during the study period did not appreciably change the 
parameter estimates. 
Conclusions: These data suggest that the greatest reductions in the TC/HDL ratio were 
among men receiving pharmacological treatment for hypertension or hypedipidemia. 13- 
JACC March 6, 2002 
year changes in the ratio were beneficially affected by lifestyle factors, but only to a mod- 
est degree. It is concerning that obesity at baseline contributes to a significant worsening 
of the ratio whereas a report of exercise only slightly improves the ratio. 
1202-88 Cholesterol Screening of Adults In the US: Role of 
Socio-demographic Factors 
(~hri~;tooher R. Bartalos, Chad Sun, Jacqueline S. Madnac, The University of Health 
Sciences, Kansas Ci~ Missouri, Medical Center of Independence, Independence, 
Missouri. 
Background: The National Cholesterol Education Program (NCEP) II & Expert Panel 
Adult Treatment Panel Ill (ATPIII) guidelines recommend a cholesterol screen every 5 
years for all adults ->20 yrs age, No information regarding the role of socio-demographic 
factors on US adult cholesterol screening has been published. 
Methods and Results: Data were extracted from the 1999 CDC Behavioral Risk Factor 
Surveillance System (BRFSS) survey. The SRFSS telephone surveyed 159,000 US 
adults regarding cholesterol screening within the last 5 years. Data were stratified by 
age, gender, ethnicity, income, education, level of insurance and the ability to afford 
health care. Overall 69% adults were screened within the last 5 yrs, which is below the 
Healthy People 2000/2010 goals of 75% & 80% respectively, However 85% adults >65 
years were screened. Adults aged _>45 years were 3.7 times more likely to receive cho- 
lesterol screening. Those with health insurance were 2.4 times more likely to receive 
screening. High school graduates or those with some college were 1.5 times more likely 
to be screened. Women were 1.2 times more likely to be screened, Those with an 
income _>$20K/yr were 1.4 times more likely to receive screening. The socio-demo- 
graphic variables had a compounding influence on cholesterol screening. For example, 
the individual <45 yrs age, who was less educated, with a lower economic status and had 
no health insurance was the least likely to report having received cholestero~ screening 
within the last 5 years (29%). 
Conclusion: Socio-demographic factors play an important role in cholesterol screening. 
This information may be used for targeted future cholesterol screening interventions. 
1202-89 Contemporary Awareness and Understanding of 
Cholesterol as a Risk Factor: Results of an American 
Heart Associat ion National Survey 
Ira S, Nash. Lori Mosca, Roger S. Blumenthal, Michael Davidson, Sidney C. Smith, 
Richard C. Pasternak, Mount Sinai School of Medicine, New York, New York. 
Public awareness and understanding of risk factors for atherosclerotic vascular disease 
are essential for successful primary and secondary prevention. The American Heart 
Association conducted a national telephone survey to assess public knowledge of the 
link between cholesterol and heart disease and the specifics of cholesterol management 
in April 2001. A national probability sample of 1114 adults age 40 years and older was 
interviewed by trained personnel using a structured format. Good regional distribution 
was achieved; 29% of respondents were over age 65, 56% were women and 87% were 
white. Most (55%) were employed and of those, 70% identified themselves as white-col- 
lar workers. Over 90% had at least a high school education and over 30% completed col- 
Ioge, Although 91% stated that it was "important o them personally to have a healthy 
cholesterol evel" (77% extremely or very important), 51% did not know their own level 
Only 40% were aware of national guidelines for cholesterol management, and 52% could 
not identify the correct desirable total cholesterol evel for a healthy adult. More people 
selected HDL than LDL as the most important lipid fraction to control (22% vs 16%). 
When asked what sources of information they rely on the most, 67% identified physicians 
and 13% stated magazines were their principal sources, while only 4% rely primarily on 
the internet. 
Conclusion: public awareness of the importance of cholesterol as a risk factor for cardio- 
vascular disease is high, but specific knowledge of cholesterol management is poor. 
Patients overwhelmingly identify physicians as their primary source of information. 
Therefore, physicians have an important opportunity to improve public understanding 
and management of lipid abnormalities, 
1202-90 Lowering LDL Cholesterol With Simvastatin, an HMG- 
CoA Reductese Inhibitor, Does Not Affect Luteal 
Function in Women 
NaDette Santoro, Diane Plotkin, Yale Mitchel, Joanna Waldstreicher, Minzhi Liu, Albert 
Einstein Col/ege of Medicine, Bronx, New York, Merck Research Laboratories, Rahway, 
New Jersey. 
Background: Cholesterol is the precursor of all steroid hormones, therefore cholesterol- 
reducing drugs could theoretically disrupt gonadal function in premenopausal women. 
Methods: This double-blind, randomized, placebo-controlled study was conducted to 
evaluate the effects of simvastatin treatment in premenopausal women. Normally cycling 
women (n=86) with elevated baseline LDL cholesterol (LDL-C) levels (130-250 mg/dL) 
were studied over six menstrual cycles. At the end of the screening phase (cycle #1), 
participants received placebo for the second menstrual cycle, and subsequently were 
randomized to receive either placebo (n=44) or simvastatin 40 mg/day (n=42) for the next 
four menstrual cycles (cycle #3-6). The second and sixth menstrual cycles were consid- 
ered baseline and treatment cycles, respectively. Participants kept a menstrual diary 
throughout he study, recording onset and duration of bleeding, and provided daily first- 
void urine samples (cycles #2 and 6). Urine samples were assayed for lutonizing hor- 
mone (LH) and pregnanediol glucuronide (PdG), the chief urinary metabolita of progest- 
erone. The primary endpoint was change in luteal phase duration as defined by the day 
of the urinary LH peak to the day preceding the onset of menstruation. The primary 
hypothesis was that there would not be a clinically significant decrease (4 days) in luteal 
phase duration between the treatment groups. 
Results'. Simvastatin Iowerad LDL-C and triglycerides by 34.3 (p<0.001) and 14.7% 
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(p<0.001), respectively, and raised high-density lipoprotein cholesterol by 4.9% 
(p<0.050). Simvastatin treatment had no clinically relevant effect on luteal phase dura- 
tion, peak PdG concentration, or integrated lutaal phase PdG concentration compared to 
the placebo group. Furthermore, the number of women experiencing anovulatory cycles 
or abnormal cycle lengths did not differ between the treatment groups. 
Conclualon: Treatment with simvastatin 40 mg/day was safe and effective at Iowedng 
LDL-C and did not adversely affect the hypothalamic-pituitary-gonadal axis in premeno- 
pausal women. 
ORAL CONTRIBUTIONS 
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873-1 Lack of Association of Celecoxib With an Increased 
Risk of Thromboembollc Events 
Gerald Faich. l, E. Allen, S. D, Ross, James B. Lafkowith, Pharmaceutical Safety 
Assessments, Inc., Narberth, Pennsylvania, Metaworks, Inc., Medford, Massachusetts. 
Background: It has been hypothesized that COX-2 specific inhibitors may increase the 
risk of cardiovascular (CV) thromboembolic events because of their inhibition of vascular 
prostacyclin synthesis and lack of an effect on platelet aggregation. 
Methods: Data from the celecoxib clinical trial database were analyzed to deteEmine the 
incidence of sedous thromboembolic events (cardiac, cerebrovascular and peripheral 
vascular events) using a methodology derived from a recent FDA cardiorenal review 
(NDA 21-042, S-007). Since aspirin use for CV prophylaxis (<325 rag/d) was permitted, 
the analysis was performed for all patients and patients not taking aspirin, 
Results: The incidence rates, patient exposure and relative risk (RR) for the long term 
safety trial CLASS (duration 12-15 rod.), 15 controlled arthritis trials (durations 3-6 rod.) 
and the open label long term safety trial (duration 24-36 mo.) for celecoxib and NSAIDs 
(naproxen, diclofenac, ibuprofen) are shown in the following table (unadjusted for differ- 
ences in study demographics and cardiac risk factors). 
Conclusion: These data suggest that celecoxib is not associated with an increased inci- 
dence of serious thromboembolic events when compared to NSAIDs and thus do not 
support the hypothesis of a class effect of COX-2 specific inhibitors on CV events. 
Disclosure: Sponsored by Pharmacia Corporation and Pfizer Inc. 
Celecoxib NSAIDs RR (95% CI) 
CLASS Rate/100 pt-yrs (total patient exposure) 
All Patients 2.24 (2,320) 
Non-ASA 1.39 (1,804) 
Adhdtis Trials 
All 1.41 (2,845) 
Non-ASA 0.73 (2,587) 
Open Label Trial 
All 1.37 (7,024) 
Non-ASA 0.80 (5,720) 
2.22 (2,203) 1.01 (0.67-1.52) 
1.34 (1,715) 1.03 (0.56-1.91) 
1.59 (1,445) 0.88 (0.52-1.55) 
1.21 (1,325) 0.61 (0.30-1.26) 
Combined Trials (CLASS, Arthritis, Open Label) 
All 1.59 (11,693) 1.97 (3,648) 0.61 (0.61-1.07) 
Non-ASA 0.92 (9,677) 1.28 (3,040) 0.72 (0.49-1.07) 
4:15 p.m. 
873-2 Ominous Prognostic Implications and Inadequacy of 
Heparin Alone for Right Heart Thrombi in Patients With 
Acute Pulmonary Embolism: Analysis of Baseline 
Characteristics, Echocardiograms, Treatment, and 
Clinical Outcomes in the International Cooperative 
Pulmonary Embolism Registry 
Adam Torbicki, Samuel Z. Gctdhaber. Nazzareno Gali6, Anna Covezzoli, Madse De 
Rosa, on behalf of the ICOPER Study Group, Institute of Tuberculosis and Lung Disease, 
Warsaw, Poland. 
Background: Management of right heart thrombi (RHTh) in acute pulmonary embolism 
(PE) is controversial, because most reports have been small case series. Therefore, we 
analyzed 2, 454 consecutive acute PE patients enrolled in International Cooperative Pul- 
monary Embolism Registry (ICOPER). 
Methods: Of the 2,454 patients, 1,143 underwent baseline echocardiography. We com- 
pared the 42 patients with versus 1,071 without RHTh. 
Result,,: Patients with RHTh had lower systolic blood pressure (116.0.+_28.0 versus 
125.7..1:25.0 mmHg, p=0.008), especially < 90 mm Hg (14% versus 5%, p=0.012), and 
more frequent right ventdcular hypokinesis (64% versus 40%, p=0.002). However, they 
were similar at admission with respect to age (62.9 versus 62.5 years), arterial oxygen 
pressure (71.3+26.0 versus 69.5+30.5 mmHg), and prevalence of cancer (14% versus 
19%). The overall mortality rate at 14 days and at 3 months was twice as high in patients 
with RHTh (21% versus 11%, and 29% versus 16%, respectively, p<0.06) and remained 
so after the exclusion of patients with right heart catheters and electrodes potentially pro. 
